Hours are depicted in Central European Time (CET)
Thursday July 1st 2021 | |
| 12.00-12.30 | Welcome: Christina Kanaka- Gantenbein, Greece, Vana Spoulou, Greece and Johannes Liese, Germany |
| 12.30-14.30 | Workshop 1: What is the burden of Varicella disease in Countries without or before universal varicella vaccination (UVV) |
| Chairs: Vana Spoulou, Greece, Sophie Alain, France | |
| Speakers: Sophie Alain, France Marion Roderick, UK Oana – Falup Pecurariu, Romania Vytautas Usonis, Lithuania Alies van Lier, The Netherlands Adamos Hadjipanayis, Cyprus Anita Heywood, Australia | |
| 15’ Discussion | |
| 14.30-15.00 | Break |
| 15.00-17:30 | Workshop 2: What is the burden of Varicella disease in countries after introduction of UVV |
| Chairs: Johannes Liese, Germany, Mona Marin, USA | |
| Speakers: Mona Marin, USA Anette Siedler, Germany Timo Vesikari, Finland Vana Papaevangelou, Greece Giovanni Gabutti, Italy Manuel Garcia Cenoz, Spain Guillermo Barrenechea, Argentina Cheng-Hsun Chiu, Taipei | |
| 20’ Discussion: Overview of the global experience with UVV | |
| 17:30-18:00 | Lecture 1 |
| Chair: George Chrousos, Greece, Maria Tsolia, Greece | |
| The global varicella burden from the past to the future Ann Gershon, USA | |
Friday July 2nd 2021 | |
| 11.00 -12.15 | Workshop 3: VZV virology: How advances in molecular biology helps our understanding on the pathogenesis of VZV |
| Chairs: George Sourvinos, Greece, Judith Breuer, UK | |
| Modulation of T cell migration and adhesion by VZV – A novel strategy to facilitate virus spread? Abel Viejo Borbolla, Germany | |
| Molecular epidemiology of VZV and vOKA strains (The Origin and Migration of Varicella Zoster Virus Strains) Judith Breuer, UK | |
| VZV- associated disease beyond Varicella and HZ Michael Gershon, USΑ | |
| 15’ Discussion | |
| 12.15-12.30 | Break |
| 12.30-13.15 | Lectures: Safety of Varicella vaccines |
| Safety of Varicella OKA/MSD vaccine. 22 years of experience Meredith Woodward, USA | |
| Safety of GSK-Oka vaccines: evidence and risk-management Giacomo Casabona, Belgium | |
| 13.15- 14:00 | Workshop 4: VZV vaccines in patients with immunocompromised and other chronic conditions |
| Chairs: Susanna Esposito Italy, Timo Vesikari, Finland | |
| Burden and complications of varicella in patients with immunocompromised and chronic conditions Johannes Liese, Germany | |
| VZV vaccines safety and efficacy in patients with immunocompromised and chronic conditions, including pregnancy Susanna Esposito, Italy | |
| 15’ Discussion | |
| 14.00-14.30 | Break |
| 14.30-15.30 | Workshop 5: What are the most important barriers associated with vaccination coverage of varicella vaccine? |
| Chairs: Paolo Bonanni, Italy, Maria Theodoridou, Greece | |
| Role of Scientific Societies and of Recommending Authorities Paolo Bonanni, Italy | |
| Role of physicians Manolis Galanakis, Greece | |
| 20’ Discussion | |
| 15: 30-16.30 | Workshop 6: Viral vs host interactions in VZV infection |
| Chairs: Ann Gershon, USA, Vana Spoulou, Greece | |
| Stem cell-derived human neurons to study VZV latency and reactivation Tomohiko Sadaoka, Japan | |
| Immune responses to VZV and vOKA strain and correlates of protection Vana Spoulou, Greece | |
| 15’ Discussion | |
| 16.30-16.45 | Break |
| 16:45-18:15 | Workshop 7: Can we predict the effects of UVV on Varicella and HZ? |
| Chair: Paolo Bonanni, Italy, | |
| Effect of Routine Varicella Vaccination on Herpes Zoster Incidence Raphael Harpaz, USA | |
| Endogenous and exogenous boosting: Modeling vs. real world Vana Papaevengelou, Greece | |
| Validity of mathematic models used for decision to introduce UVV Johannes Horn, Germany | |
| 15’ Discussion | |
| 18:15-18:30 | Lecture |
| Chair: Michael Oxman, USA | |
| From varicella to Zoster Vaccines Timo Vesikari, Finland | |
Saturday July 3rd 2021 | |
| 10.00-10.30 | HZ vaccines (GSK, Merck) |
| Chair: Timo Vesikari, Finland The recombinant zoster vaccine: a review of key clinical data Speakers: Nicolas Lecrenier, Belgium | |
| 15’ Discussion | |
| 10.30-12.00 | Workshop 8: What is the burden of herpes zoster (HZ) in adults and how it can be reduced by currently available HZ vaccines? |
| Chair: Timo Vesikari, Finland | |
| The burden of the herper zoster in adults TBA | |
| Efficacy and safety of licensed HZ vaccines: in special patient groups Elderly Michael Oxman, USA | |
| Recommendations and implementation and acceptance of vaccination against HZ in Germany Anette Siedler, Germany | |
| 15’ Discussion | |
| 12.00-12.15 | Break |
| 12.15-13.20 | Workshop 9: How far can the burden of varicella and HZ be reduced |
| Chair: Carlo Giaquinto, Italy | |
| Cost effectiveness of UVV and Herpes Zoster vaccination programs Alies van Lier, The Netherlands | |
| Modelling the impact of combined vaccination programs against VZ and HZ Valentina Marziano, Italy | |
| What is the best way to implement varicella and HZ immunization? The review of current evidence” David Greenberg, Israel | |
| 13:20-14:00 | Panel Discussion |
| Implementing UVV and HZ: Barriers to overcome and the way to move forward Vana Spoulou, Johannes Liese, Ann Gershon, Carlo Giaquinto | |
| Symposium Closing | |